AbbVie's Q2 2026 print is a case of a real, narrow miss overshadowing genuinely strong underlying growth. Revenue beat estimates comfortably, and the two drugs carrying AbbVie's post-Humira future — Skyrizi and Rinvoq — both grew north of 24%. Shares still fell nearly 5% premarket on a 6-cent adjusted EPS miss and full-year guidance that came in below consensus.
The Headline Numbers
| Metric | Q2 2026 | Estimate | Result |
|---|---|---|---|
| Revenue | $16.99B | $16.77B | Beat, +10.2% YoY (+9.5% operational) |
| Adjusted EPS | $3.65 | $3.71 | Miss |
| GAAP diluted EPS | $2.03 | — | vs. $0.52 a year ago |
| FY2026 adjusted EPS guidance | $13.87–14.07 | ~$14.12 midpoint expected | Lowered, below consensus |
Revenue growth was genuinely strong and broad-based; the problem sat entirely on the profit line, where a real (if narrow) miss combined with guidance moving the wrong direction to produce the stock's reaction.
Why the Miss Happened — and Why It's Mostly Not a Growth Problem
AbbVie's lowered full-year adjusted EPS guidance (to $13.87–14.07 from a prior $13.91–14.11) carries two specific, disclosed drags that explain most of the shortfall. First, a $0.14 per share dilutive impact tied to the pending acquisition of Apogee Therapeutics — a roughly $10.9 billion deal expected to close in Q3 2026. Second, $0.58 per share of unfavorable year-to-date impact from acquired IPR&D and milestone expenses, the accounting cost of AbbVie continuing to license and acquire pipeline assets. Both are the direct financial cost of AbbVie actively building its next wave of growth drivers, not evidence the existing business is slowing.
CEO Robert A. Michael's framing leaned into exactly that read: "AbbVie delivered another excellent quarter, marked by outstanding execution and pipeline advancement. Based on our substantial momentum, AbbVie's long-term outlook remains very strong." That's the kind of statement that's easy to dismiss as boilerplate, but the segment data underneath it actually backs it up more than the stock reaction would suggest.
The Real Story: Skyrizi and Rinvoq Are Still Compounding Hard
Immunology revenue hit $8.786 billion, up 15.1%, with Skyrizi at $5.505 billion (+24.4%) and Rinvoq at $2.525 billion (+24.5%) — both drugs growing at essentially identical, still-accelerating rates two-plus years into their run as AbbVie's replacement for Humira. Humira itself continued its expected patent-cliff decline, down 35.9% to $756 million — a well-understood, priced-in trend at this point, not new information.
Neuroscience grew 20.3% to $3.228 billion, with Vraylar at $1.071 billion, Botox Therapeutic at $1.042 billion, and combined Ubrelvy/Qulipta revenue at $742 million — a genuinely diversified growth engine beyond the immunology franchise, and arguably the more underappreciated part of this quarter's results.
Oncology was the one soft spot, down 1.5% to $1.650 billion, as Imbruvica's decline (−29.4% to $532 million) outpaced Venclexta's growth (+11.6% to $771 million) — a franchise still working through its own competitive and patent pressures, distinct from the broader growth story elsewhere.
Our Read
This looks like a case where the market applied a standard "beat-the-number-or-else" reaction to a quarter whose actual disclosed shortfall came almost entirely from AbbVie spending money on its own future pipeline (Apogee, IPR&D/milestones) rather than from any deceleration in the businesses already generating revenue. Skyrizi and Rinvoq growing in the mid-20s YoY, two-plus years post-Humira-cliff, is close to the best-case outcome the post-Humira transition thesis could have asked for. The stock's reaction says more about how unforgiving the market currently is toward any EPS miss — even a 6-cent one, even with a fully disclosed, one-time-flavored cause — than it does about AbbVie's underlying trajectory.
What to Watch
- The Apogee Therapeutics deal closing (expected Q3 2026) and whether the dilutive EPS impact tracks the guided $0.14, or comes in better/worse than modeled.
- Whether Skyrizi and Rinvoq's mid-20s growth rate holds as the comparison base gets larger — the single most important number for the whole post-Humira thesis.
- Oncology's competitive position, given Imbruvica's ongoing decline isn't yet being fully offset by Venclexta's growth.
- IPR&D and milestone expense trends for the rest of 2026 — a recurring drag on headline EPS that's really a proxy for how aggressively AbbVie continues to build its pipeline.
The Bottom Line
AbbVie's Q2 2026 beat on revenue, missed narrowly on adjusted EPS, and got a nearly 5% stock decline for it — but the disclosed reasons for the miss (deal dilution, IPR&D spend) are the cost of building the company's next decade of growth, not a sign the current one is faltering. Skyrizi and Rinvoq both growing north of 24% is the number that should matter most here, and it's the number the stock's reaction mostly ignored.
AbbVie Inc. (NYSE: ABBV) reported Q2 2026 revenue of $16.99B (+10.2% YoY), beating consensus, with adjusted EPS of $3.65 missing the $3.71 estimate. Shares fell approximately 4.7% in premarket trading on the EPS miss and lowered full-year guidance.